Pfizer presents 45 oncology abstracts at ESMO 2026
Share
Pfizer (NYSE:PFE) announced it will present data from 45 oncology research abstracts at the European Society for Medical Oncology Congress 2026, taking place October 23–27 in Madrid, Spain.
Pfizer (NYSE:PFE) announced it will present data from 45 oncology research abstracts at the European Society for Medical Oncology Congress 2026, taking place October 23–27 in Madrid, Spain.
Pfizer (NYSE:PFE) announced on June 8, 2026, that the U.S. Food and Drug Administration (FDA) has granted an expanded indication for HYMPAVZI® (marstacimab-hncq). The therapy is now approved for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 6 years of age and older with hemophilia A or B, both with and without inhibitors.
Pfizer (NYSE:PFE) announced today that its Chief Financial Officer, Dave Denton, will depart the company on August 15, 2026, to accept a new position within the consumer goods industry.
Pfizer Inc. Chief Executive Officer Albert Bourla says President Donald Trump's nominee to lead the Centers for Disease Control and Prevention is a good choice. Bourla says Erica Schwartz is a "very credible scientist." Bourla also talks about earnings, their drug pipeline and doing business in China. He speaks to Bloomberg's David Westin.
Nina Trentmann, Senior Editor at Bloomberg News, discussed the recent appointment of Dave Denton, formerly Pfizer's CFO, as Nike's new Finance Chief. While some analysts have expressed concerns about Denton's lack of direct retail and apparel industry experience, Trentmann noted that for large companies like Nike and Pfizer, deep industry knowledge may be less critical than experience managing a complex, global business with a significant market capitalization and extensive supply chains. She speaks with Romaine Bostick & Katie Greifeld on "The Close."
_1431358_640x360_2505225795777-640x360.webp&w=3840&q=75)
